Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

    Results show prolonged courses of stable disease and excellent
    tolerability and indicate potential for use as combination treatment for
    cancer

QUEBEC CITY, Sept. 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer. Under the supervision of lead investigator, Daniel D. Von Hoff, MD, Senior Investigator and Physician in Chief at the Translational Genomics Research Institute in Scottsdale, Arizona, this open-label, dose-escalation, multi-center, intermittent treatment Phase 1 trial was conducted at 2 clinical sites in Scottsdale: the Mayo Clinic with principal investigator Donald W. Northfelt, MD, and at Premiere Oncology with principal investigator David Mendelson, MD.

Results

The study was performed in two parts and included 42 patients overall. In Part I, 22 patients were studied on doses ranging from 13 to 800 mg/week. In Part II, the weekly dose was split into 3 doses taken 8 hours apart, and ultimately, 20 patients received doses from 120 to 600 mg/week. Stable disease with time to failure ranging from 20 to 60+ weeks was achieved in 12 patients with various cancer types, including melanoma and cancers of the colon/rectum, lung, pancreas, prostate, tongue, trachea and thyroid. In several of these patients, the duration of stabilization exceeded the duration of disease control on previous treatment regimens. Except for a dose-limiting gastrointestinal reaction in a patient with pre-exis
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... Top LASIK surgeons and recognized refractiv...ASIK Surgeons made brought their fellow surgeons u...rection surgery, cataract surgery, and ophthalmolo...cademy of Ophthalmology (AAO) annual meeting in Sa.... Shachar Tauber, Dr. David Huang, MD, Dr. Randy E...
(Date:11/18/2009)...National Institute of Standards and Technology (NI...ive method for detecting and measuring elusive haz...sible spoilage in food or pesticides distributed i...ore sensitive than conventional techniques for det...ike water molecules, having distinct electrically ...
(Date:11/18/2009)...er,s experience in data analysis combined with Bio... kits and curricula provide state-of-the-art s...TON, Ore., Nov. 18 Vernier Softwar...nce interfaces, sensors, and software and Bio-Rad ...nd distributor of life science research and clinic...
(Date:11/18/2009)... Promega Corporation and SwitchGear Genomics...otein interactions. , Mad... Corporation and SwitchGear Genomics announce a no...ions. Results of a study using the HaloCHIP™...trate the ability to correlate DNA binding events ...
Breaking Biology Technology:Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9Prototype NIST method detects and measures elusive hazards 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity 2
...eekly Dosing, SAN DIEGO, Nov. 13 Ambrx Inc. toda...rating that ARX201, the company,s,long-acting huma...boration,with Merck Serono, normalized insulin-lik...an acceptable safety and tolerability profile in a...of this trial support further,evaluation of ARX201...
... CITY, Nov. 13 /PRNewswire-FirstCall/ - AEterna Ze...iopharmaceutical company focused on,endocrinology ...ng results,for the third quarter ended September 3...intment on September 1, 2008, of Juergen Engel, Ph...eplacing Juergen Ernst who had been acting as I...
...uticals Corp. (Nasdaq: MEMY ), today reported its...tember 30, 2008., "Our results reflect continued ...nt to translate that progress into innovative ther...ief Executive Officer of Memory,Pharmaceuticals. "...r,ongoing Phase 2 trial for R3487/MEM 3454 in cogn...
Other Biology Technology:Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 2Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 3AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 7AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 8AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 7Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 8
(Date:11/19/2009)...urring brain chemical with an unwieldy name: 4-hyd...sed or used as a date-rape drug. , Now, a team ...w routes by which 4-HB is metabolized by the body....Michael Gibson, professor and chair of biological ...a member of the research team. "It may provide ne...
(Date:11/19/2009)... ants, which cultivate fungus for food, have many ... to the list: the ant farmers, like their human co...make their gardens grow. The finding, reported thi...ts a previously unknown symbiosis between ants and...r ants have come to dominate the American tropics ...
(Date:11/19/2009)...t crop in many countries of the world. It is widel...ustrial materials. It also is considered an exempl...ular evolution, and genome architecture. The autho...ction used the first description of the B73 maize ...ons in genetics and plant biology. The ten papers ...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Like humans, ants use bacteria to make their gardens grow 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 1nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 2nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 3nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 4New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 1New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 2New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 3New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 4New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 5New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 6PharmaSURVEYORs Advanced Drug Safety Service Connects to Microsoft HealthVault 48576 1PharmaSURVEYORs Advanced Drug Safety Service Connects to Microsoft HealthVault 48576 2
...orals that responds to day/night cycles, which pro...rals work together with their plankton partners. ...rgest biological constructions in the world, spraw... seafloor yet provide habitats for more than 30% o...bundant food, corals have developed a close relati...
...rbon dioxide from burning of fossil fuels might be...are phased out within the next few decades, say re...s should be used sparingly as well, but that far g...ain target of reductions. Their study appears in t... The burning of fossil fuels accounts for about 8...
...ws Media,Group,s, C4ISR Journal will host its 8th ...Big 25 Awards Banquet on October 16-17, 2008 at th...., The conference will address the importance of ...ns including:, -- Combat Communications -- In... Support -- From Net-Centric Warfare to Knowledge...
Other Biology News:Curbing coal emissions alone might avert climate danger, say researchers 2Curbing coal emissions alone might avert climate danger, say researchers 3Annual C4ISR Integrated Conference and Big 25 Awards Banquet 2Annual C4ISR Integrated Conference and Big 25 Awards Banquet 3
pORF39-Sh ble from InvivoGen
SkanWasher 400 from Molecular Devices
pORF39-Hph from InvivoGen
...late is designed to allow neomycin/kanamycin selec...-PGK-gb2-neo-FRT template encodes the neomycin/kan...c promoter (gb2) for expression of kanamycin resis... for expression of neomycin resistance in mammalia...
Biology Products: